Processa Pharmaceuticals financials
$1.76−4.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M | -$15.1M |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$11.4M | -$19.0M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-10.36 | $-96.78 | $-212.00 | $-851.25 | $-375.00 | $-1270.00 |
| EBITDA | -$14.0M | -$12.1M | -$11.5M | -$19.5M | -$11.3M | -$14.3M |
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M | -$3.1M |
| Free cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | — | — |
| Diluted shares | 1.3M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $163.4K |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M | $25.2M |
| Total liabilities | $2.2M | $1.5M | $797.5K | $1.1M | $978.4K | $2.3M |
| Shareholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M | $22.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology